• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Rheumatol Int . Outcomes of multisystem inflammatory syndrome in children temporally related to COVID-19: a longitudinal study

tetano

Editor, Senior Moderator
Rheumatol Int


. 2021 Oct 19.
doi: 10.1007/s00296-021-05030-y. Online ahead of print.
Outcomes of multisystem inflammatory syndrome in children temporally related to COVID-19: a longitudinal study


Narendra Kumar Bagri[SUP] 1 [/SUP], Rakesh Kumar Deepak[SUP] 2 [/SUP], Suneeta Meena[SUP] 3 [/SUP], Saurabh Kumar Gupta[SUP] 4 [/SUP], Satya Prakash[SUP] 5 [/SUP], Kritika Setlur[SUP] 5 [/SUP], Jagatshreya Satapathy[SUP] 5 [/SUP], Karan Chopra[SUP] 5 [/SUP], Ashish Datt Upadhyay[SUP] 6 [/SUP], Sivasubramanian Ramakrishnan[SUP] 4 [/SUP], Rakesh Lodha[SUP] 5 [/SUP], Lalit Dar[SUP] 7 [/SUP], Anjan Trikha[SUP] 8 [/SUP], Sushil Kumar Kabra[SUP] 5 [/SUP]



Affiliations

Abstract

To study the clinical, laboratory characteristics and outcomes of multisystem inflammatory syndrome in children (MIS-C) temporally related to coronavirus disease 2019 (COVID-19) in a resource-limited setting. All children meeting the World Health Organization case definition of MIS-C were prospectively enrolled. Baseline clinical and laboratory parameters were compared between survivors and non-survivors. Enrolled subjects were followed up for 4-6 weeks for evaluation of cardiac outcomes using echocardiography. The statistical data were analyzed using the stata-12 software. Thirty-one children with MIS-C were enrolled in an 11-month period. Twelve children had preexisting chronic systemic comorbidity. Fever was a universal finding; gastrointestinal and respiratory manifestations were noted in 70.9% and 64.3%, respectively, while 57.1% had a skin rash. Fifty-eight percent of children presented with shock, and 22.5% required mechanical ventilation. HSP like rash, gangrene and arthritis were uncommon clinical observations.The median duration of hospital stay was 9 (6.5-18.5) days: four children with preexisting comorbidities succumbed to the illness. The serum ferritin levels (ng/ml) [median (IQR)] were significantly higher in non-survivors as compared to survivors [1061 (581, 2750) vs 309.5 (140, 720.08), p value = 0.045]. Six patients had coronary artery involvement; five recovered during follow-up, while one was still admitted. Twenty-six children received immunomodulatory drugs, and five improved without immunomodulation. The choice of immunomodulation (steroids or intravenous immunoglobulin) did not affect the outcome. Most children with MIS-C present with acute hemodynamic and respiratory symptoms.The outcome is favorable in children without preexisting comorbidities.Raised ferritin level may be a poor prognostic marker. The coronary outcomes at follow-up were reassuring.

Keywords: Coronary artery outcomes; MIS-C; MIS-C and Kawasaki disease; SARS-CoV-2.
 
Back
Top Bottom